The cloning of the cystic fibrosis (CF) gene A prerequisite to an informed decision to undergo any screening or diagnostic test is knowledge of the test.3 Indeed, some argue that the effectiveness of such a screening programme should be assessed by whether the participants have become fully informed.4
However, to be effective and useful, educational materials must meet the specific needs of the target population.5
The use of a questionnaire to assess patients) attitudes to information leaflets has been described.67 Before committing ourselves to a final version of the information leaflet designed for this trial, we tested the acceptability and usefulness of a preliminary version on our target population, by means of a self administered questionnaire.
Subjects and methods A pilot trial was run in one antenatal booking clinic for a period of 14 weeks. Along with their booking clinic appointment, patients received a copy of the information leaflet outlining the purpose and process of prenatal CF carrier screening ( (1) Had you heard of the disease cystic fibrosis before you read the leaflet? (1) kept informed of all aspects of antenatal genetic screening.8 In this study, television was the leading source of information about CF. A considerable number of respondents were acquainted with the disease through women's journals and charity appeals. Knowledge of CF was acquired by a number of women through their occupation and in three cases by virtue of having a distant family history of the disorder. The majority (96%) of antenatal patients stated that they found the leaflet easy to understand (table 3) . There was no correlation between difficulty understanding the leaflet, or failing to understand the purpose of CF screening, and declining the test. All 10 respondents who declined the test found the leaflet easy to understand and stated that they felt they understood the purpose of CF screening. One woman took the CF test, despite finding the leaflet difficult to understand and not understanding the purpose of CF screening.
There is a danger in designing an information leaflet that one may make it either too simple or too complex. Many women are confident and articulate users of the antenatal care system and can cope with detailed information. Others lack the basic knowledge to know the right questions to ask. Our solution has been to design a comparatively simple leaflet and to train midwives to pick up those cases who are unsure about what is being offered. A genetic nurse is on standby to give one to one counselling and answer the more sophisticated questions.
Most women (65%) stated they had only read the leaflet once before feeling they understood it (table 2) . Antenatal bookers receive a considerable volume of material to read along with their clinic appointment and may find they have limited time to read and absorb it all. Those who enter the CF screening trial must sign a consent form and in addition the midwife responsible for booking a patient is instructed to do his or her utmost to ensure that a participant understands the purpose of the screening test. Nevertheless, studies do indicate that a lack of knowledge and understanding of women participating in prenatal screening programmes is an area for concern'0 and researchers have attempted to design instruments whereby knowledge of such tests can be measured.3 CF carrier screening may carry more obscure risks and considerations than other antenatal screening tests, notably Analysis of discussion with significant others, among those women who took the decision alone, to enter the CF screening trial.
perceived change of self image in those identified as gene carriers." A prerequisite of prenatal CF carrier screening is cooperation of the male partner. Most partners (63%) read the prescreening leaflet and were involved in the test decision (table 2) . The partners of all 10 women who declined the test had read the leaflet. Although two of these women took the decision to decline the test alone, they had discussed it with their partner. Of those who found the leaflet difficult to understand, five partners read the leaflet and three also found it difficult to understand. Nevertheless, they were party to the decision to be screened. All partners of those women who felt they did not understand the purpose of CF screening were involved in discussion and decision making, although only one had read the leaflet.
Twenty-one respondents (14%) who entered the trial discussed taking the test with a friend and 18 (12%) with a relative. Only five respondents had talked with their GP and one woman to her health visitor. Fifty-two women made the decision to take the test alone. A concern which emerged from this study is that 13 (9%) women took the decision to be tested without discussing the test with either their partner or other significant person (figure). Evidence suggests that social network and social support play an important role in health, individual decision making, and behaviour. Moreover, social support is known to serve a protective function by moderating the impact of stress and facilitating coping.'2 It could be hypothesised that good social support will contribute positively to a woman's adjustment to being a CF carrier. It has been pointed out that the whole area of psychosocial support has been neglected in the provision of antenatal care and that careful assessment of a woman's social support system should be an integral part of the antenatal booking procedure. '3 Identifying vulnerable women in advance of any screening test is important. This study suggests that around 10% of women booking at the antenatal clinic may have reduced perceived or received social support. Further research is needed to substantiate this.
Those women who decided to accept the CF screening test did so, in 76% of cases, to avoid the birth of a child with CF. In addition, 71% stated, either with or without saying they wished to avoid having a CF child, that they were interested to know if they carried a single CF gene. In 16% of cases, the male partner's wishes had been instrumental in their decision to be tested. Those who gave additional reasons for being screened (7%) stated they wished to help with research or contribute to a better understanding of the disorder. Commendable though this is, we have subsequently discouraged women from entering the trial for these reasons. A positive test result has far reaching consequences which prospective participants must consider carefully.
A vast majority (99%) of women who accepted the screening test thought it 'not very likely' or 'most unlikely' that they would be found to be carriers (table 3) . Nevertheless, 41% were still 'anxious' or 'slightly apprehensive' about being screened. There was no correlation between difficulty in understanding the leaflet or understanding the purpose of CF screening and feelings of anxiety towards being tested. The one participant who stated the test made her feel anxious had taken the decision to be tested only after discussion with her GP. She did not think it very likely that she would carry a single CF gene. The whole area of anxiety generated by this programme of screening will be explored in greater depth.
"More about people with the disease, effects, lifespan, etc" was a typical request made by the 15% of respondents who felt that the leaflet should give more information (table 2) . However, those who felt the leaflet offered sufficient information frequently commented that, although they would like to know more about the disease, additional information in the leaflet might only serve to confuse. As a compromise we expanded, slightly, the section of the leaflet entitled 'The disease cystic fibrosis' and, as an adjunct, designed a separate leaflet devoted to the disorder. This leaflet is made readily available at the antenatal clinic.
Good quality educational materials can help promote the relationship between the patient and the health care professional as well as enhancing patient knowledge and self care. 5 Quality of text will be determined by its readability and must, therefore, be written on a level that is appropriate for the target population. Moreover, readability will be influenced by the content, style, layout, colour, and illustrations. It is unrealistic to believe that a leaflet can provide blanket coverage of all aspects of antenatal CF carrier screening. A mixture of information giving, teaching, and counselling is needed. Nevertheless, the delivery of information by leaflet is one very important strategy. We shall, therefore, continue to evaluate the delivery of prescreening information by leaflet for the duration of this trial.
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